Business Wire

Halfords Delivers Consistent and Convenient Shopping Experiences with Juniper Networks’ AI-driven Wired and Wireless Access Solutions

Share

Juniper Networks ®, (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Halfords, the UK’s leading provider of motoring and cycling products and services selected Juniper’s AI-driven wired and wireless access solutions in its stores, garages and offices to serve as a flexible foundation for its business growth and operational efficiency. The 125-year-old company has invested heavily to accelerate its digital transformation, leveraging the benefits of Mist AI and the cloud to create better commercial services and a unified, omnichannel retail experience for its customers. Halfords has reduced network-related trouble tickets by 100 percent and has seen a 35 percent improvement in uptime in the garages and stores where the deployment has been completed.

The Juniper® AI-driven network provides an agile digital foundation for Halfords’ continued success and drives a more consistent and convenient customer experience across locations and channels. It can tailor communications to Halfords Motoring Club members when they come to the store. The new network provides employees details about products such as child seats, cycle racks and roof racks, so they can have informed conversations with customers and sell with greater confidence.

Halfords pivoted during the pandemic, with strong growth in online sales and the addition of contactless tactics such as click-and-collect in its parking lots. Its innovative mobile field service software was key to delivering 70,000 services safely and efficiently per week for more than four years at its auto centers and customers’ homes. Many pandemic-motivated shopping behaviors are now permanent, requiring an IT infrastructure that is flexible and scalable enough to support changing customer demands.

As shoppers return to stores to test drive an electric bike, get an oil change or replace worn tires, for example, reliable wired and wireless connectivity is essential for both workers and shoppers alike. Halfords had an aging in-store network that was increasingly a roadblock to sales and service due to inconsistent performance and difficult troubleshooting, which resulted in poor user and operator experiences. To address this, the retailer is now deploying a Juniper wired and wireless network across its retail stores, auto centers and offices. Mist AI works in conjunction with Juniper Access Points to deliver scalable and reliable Wi-Fi 6 and virtual Bluetooth® LE services to Halfords’ staff and customer smartphones, point-of-sale devices, in-store video displays and other connected devices. Juniper EX Series switches provide high-performance, secure access to wired devices with AI-driven automation and insights for easy provisioning, troubleshooting and operations. Marvis™, the industry’s only virtual network assistant driven by Mist AI, provides proactive actions for easy fault identification and self-driving network operations for fast and proactive correction. Juniper is a Leader in the 2022 Gartner® Magic Quadrant™ for Enterprise Wired and Wireless LAN Infrastructure for the 3rd year in a row, positioned highest on the ability to execute axis and furthest to the right on the completeness of vision axis.

Halfords plan to transform its network further with the modernization of its WAN, which connects its 1400+ stores, auto centers and mobile service vans. To achieve this, they are also planning to deploy Juniper’s AI-driven SD-WAN solution, which leverages the same cloud and Mist AI engine as their new wired and wireless network. By deploying a full-stack Juniper solution, Halfords can achieve superlative insight into end-to-end user experiences and the superior automation from client-to-cloud.

Halfords worked with ConnectedID, a Juniper partner, to create the optimal network architecture, working on the design, validation and testing to ensure that the Juniper solutions met Halfords’ strategic goals.

Supporting Quotes:

“The network is a utility. It is a big part of our digital transformation journey, and we needed a very intelligent, secure network with next-generation capabilities. Juniper is a disruptor in the industry. The network user experience that it offers far exceeds anything else in the market. The ease of operations and self-healing capabilities of Juniper’s technology, along with the user experience metrics it delivers for Halfords, are outstanding.”

- Neil Holden, Chief Information Officer, Halfords

“Smart retailers like Halfords are leveraging AI technologies to ensure customers’ shopping experiences are positive at every touchpoint. Halfords has invested in Juniper’s AI solutions to build a more detailed picture of its customers to keep up with changing consumer behavior. Mist AI helps Halfords optimize user experiences and simplify IT operations with automated network assurance and the proactive problem detection and resolution. Users and devices have predictable connectivity and the number of network-related trouble tickets have dropped by 100 percent.”

- Gos Hein van de Wouw, Vice President, Enterprise, EMEA, Juniper Networks

Additional Resources:

About Juniper Networks

Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

Category – AI

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Pelin Murphy
Juniper Networks
+44 (0) 1372 385 686
pelin@juniper.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye